MetaCap

Rani Therapeutics Holdings Inc. Class A (RANI)

NASDAQ: RANIHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.5111-0.0695 (-11.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RANI stock chart

Technical analysis

Key statistics

All statistics
Market cap
$59.03M
EPS (TTM)
-$0.06
52-week range
0.502 – 1.69
Day range
0.5101 – 0.5819
Volume / Avg
457.42K / 545.67K
Beta
—

52-week range

$0.502$1.69

RANI stock today

On Nov 20, RANI ended the session at $0.5111, shedding $0.0695 (11.97%), versus the S&P 500's 3.70% decline. At this level, RANI sits near the bottom of its 52-week range of $0.502 to $1.69: 69.8% below the high, set on Nov 21, 2025 and 1.8% above the low. RANI is down 62.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 68.6%.

Rani Therapeutics has posted a net loss over the last twelve months (EPS of -$0.06), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Rani Therapeutics

Company profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Talat Imran
Headquarters
San Jose, CA
Employees
69
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Rani Therapeutics generated $1.6 million in revenue, up 58.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Rani Therapeutics reported a net loss of $29.7 million, compared with a loss of $30.0 million a year earlier. Operating margin was -2346.0%.

Rani Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.63M$1.03M$0$0$2.72M
Growth+58.85%——-100.00%+488.10%
Net income$-29.67M$-30.02M$-33.97M$-30.59M$-8.33M
EPS (diluted)$-0.45$-1.05$-1.33$-1.28$-0.43

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$7.20+1308.73%

  • Strong buy 1
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $11.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.04 vs $-0.05
Surprise
+20.00%

RANI news

All RANI news

Rani Therapeutics peers

Health Care sector
RANI peer companies
CompanyPrice% ChgMarket capCompare
TENXTenax Therapeutics Inc.1.25-10.07%$56.92Mvs RANI
IBIOiBio Inc.0.8001-0.11%$56.37Mvs RANI
KZIAKazia Therapeutics Limited ADR4.92-8.38%$56.22Mvs RANI
VTVTvTv Therapeutics Inc. Class A15.51-5.20%$62.22Mvs RANI
AZRAzora Therapeutics Inc.3.85-0.52%$55.00Mvs RANI
BOLDBoundless Bio Inc.2.32-2.52%$54.78Mvs RANI
FBIOFortress Biotech Inc.1.90+7.34%$64.11Mvs RANI
XLOXilio Therapeutics Inc.7.56-1.11%$53.40Mvs RANI

Indexes, lists and sector

Rani Therapeutics stock FAQ

What is Rani Therapeutics's stock price today?

RANI last traded at $0.5111 as of Nov 20, 4:00 PM EST, down 11.97% on the day. Prices are delayed at least 15 minutes.

Who is Rani Therapeutics's CEO?

Mr. Talat Imran is the chief executive officer of Rani Therapeutics Holdings Inc. Class A, which has about 69 employees.

What is the RANI 52-week high?

The 52-week high for RANI is $1.69 and the 52-week low is $0.502. The stock is currently 69.8% below its high.

Compare RANI